-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the team of Professor Xia Ningshao from Xiamen University published a report entitled “A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV- 2 infection and transmission in hamsters" research paper
.
The research has developed a new coronavirus recombinant protein vaccine based on recombinant spike protein and innovative adjuvants.
The immunogenicity and effectiveness of the vaccine have been verified in a variety of animal models, providing a basis for the prevention and control of the new coronary pneumonia epidemic.
The coronavirus pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is changing the pattern of global public health
.
So far, 218 countries and regions around the world have confirmed SARS-CoV-2 infection, with more than 188 million confirmed COVID-19 cases and more than 4 million deaths
.
At present, a variety of vaccines have been marketed or used in emergency around the world.
Clinical trials and real-world research data have proved that vaccination with the new crown vaccine can effectively reduce the risk of viral infection and reduce the severity of the disease
.
However, whether or not individuals can obtain sterilizing immunity against the new coronavirus through strong vaccine immunization, thereby effectively suppressing the risk of virus transmission, remains to be further studied and clarified
.
In this study, the researchers designed a novel coronavirus recombinant protein vaccine StriFK-FH002C based on the immunogen StriFK of the SARS-CoV-2 recombinant spike protein expressed in CHO cells and the innovative adjuvant FH002C
.
The vaccine induces high titers of neutralizing antibodies in mice, hamsters and cynomolgus monkeys, which is 30 to 250 times higher than the neutralizing antibodies of human COVID-19 convalescent plasma.
It is in terms of the speed and strength of neutralizing antibodies.
In the protective test, the researchers used the hamster animal model that simulates severe new coronary pneumonia in humans, using two modes of direct challenge and close transmission to prove that StriFK-FH002C immunity can give hamsters good protection against the new coronavirus.
Effect: Significantly reduce the viral load of respiratory tract tissues such as turbinates, trachea, lungs, etc.
, so as to prevent the test animals from lung tissue lesions caused by the new crown infection
.
More importantly, the study used an air transmission test to show that StriFK-FH002C vaccination can not only protect the vaccinated animals, but also effectively reduce the risk of virus transmission from vaccinated individuals to unvaccinated individuals and cause disease
.
By comparing and analyzing the changes in antibody response before and after the challenge, studies have confirmed that in at least some animals, StriFK-FH002C vaccine immunization can confer sterilizing immunity against the new coronavirus (sterilizing immunity)
.
Doctoral student Wu Yangtao, doctoral student Huang Xiaofen, postdoctoral fellow Yuan Lunzhi, postdoctoral fellow Wang Shaojuan, postdoctoral fellow Zhang Yali and doctoral student Xiong Hualong are the co-first authors of the paper
.
Professor Xia Ningshao, Professor Yuan Quan, Professor Zhao Qinjian, Assistant Professor Zhang Tianying, Professor Zhang Jun, Professor Guan Yi and Associate Professor Zhu Huachen of the University of Hong Kong are the co-corresponding authors of the paper
.
Paper link:
https://stm.
